BioIntel AI
  • Home
  • Blog
  • About

Blog

AI in Life Sciences

All Posts
AI in Drug Discovery
AI in Clinical Trials
AI for Medical Affairs
AI in Regulatory & Compliance
AI Tools & Platform Reviews
AI News & Trends
AI Biotech & Pharma Stocks
  • The EU AI Act and Pharma Compliance: What Life Sciences Companies Need to Know

    July 9, 2025

    The EU AI Act is reshaping how pharmaceutical and life sciences companies develop and deploy AI — from clinical trials to diagnostics. As the world’s first comprehensive AI regulation, it introduces strict rules around risk classification, human oversight, and audit trails. If your company is building AI-powered tools or seeking approval in the EU and…

    Read more: The EU AI Act and Pharma Compliance: What Life Sciences Companies Need to Know
    The EU AI Act and Pharma Compliance: What Life Sciences Companies Need to Know
  • FDA AI Food Safety: How ELSA is Changing Import Oversight

    July 7, 2025

    Summary:FDA ELSA AI food safety efforts mark a turning point in how the agency screens food imports, using machine learning to flag high-risk shipments. In June 2025, the FDA announced the agency-wide launch of a powerful new AI tool named ELSA (Enhanced Learning and Surveillance Algorithm). Designed to improve how the FDA screens imported foods,…

    Read more: FDA AI Food Safety: How ELSA is Changing Import Oversight
    FDA AI Food Safety: How ELSA is Changing Import Oversight
  • FDA’s 2025 Draft Guidance on AI in Drug Development: What It Means for Biopharma

    July 3, 2025

    AI in drug development is rapidly transforming how therapies are discovered, tested, and submitted for approval—but until now, regulatory guidance has struggled to keep up. That changed in January 2025, when the U.S. Food and Drug Administration (FDA) published its first-ever draft guidance focused on the use of AI to support regulatory decision-making in the…

    Read more: FDA’s 2025 Draft Guidance on AI in Drug Development: What It Means for Biopharma
    FDA’s 2025 Draft Guidance on AI in Drug Development: What It Means for Biopharma
  • How the FDA Is Quietly Rewriting the Rules for AI in Healthcare

    June 17, 2025

    FDA AI regulation in healthcare is undergoing a major transformation. The U.S. Food and Drug Administration is quietly reshaping how artificial intelligence is governed in medicine — a shift that could influence everything from how your doctor diagnoses illness to how your Apple Watch monitors your heart. AI has already become a powerful force in…

    Read more: How the FDA Is Quietly Rewriting the Rules for AI in Healthcare
    How the FDA Is Quietly Rewriting the Rules for AI in Healthcare
  • Agentforce in Life Sciences: AI Use Cases in Pharma and Medtech

    May 16, 2025

    Agentforce applies AI-driven “digital labor” to life sciences workflows, helping scientists and field teams spend less time on manual tasks.The life sciences industry – spanning pharmaceutical, biotech, and medical device companies – is embracing Salesforce Agentforce to drive efficiency and innovation. Agentforce is an “agentic” AI platform that allows organizations to deploy autonomous AI agents…

    Read more: Agentforce in Life Sciences: AI Use Cases in Pharma and Medtech
    Agentforce in Life Sciences: AI Use Cases in Pharma and Medtech

AI Innovations

Explore how AI is revolutionizing drug discovery, clinical trials, and healthcare analytics.

Menu

  • Home
  • Blog
  • About

Contacts

insights@BioIntelAI.com

Socials

  • LinkedIn

© 2025 BioIntel AI, a division of A&Y Trading Co Inc. All rights reserved. Terms & Privacy Policy

Notifications